FDA-approved GLP-1 medications

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) as their FDA prescribing information describes them: what each product is approved for, the labelled schedule, and what the trials behind each label reported. Same ingredient does not mean same product.

• Ozempic dosage chart from the FDA label

  The Ozempic (semaglutide) dose schedule as the FDA label states it: start, escalation, maintenance, maximum, pen strengths and label changes.

• Zepbound weight loss chart: SURMOUNT trial results

  Weight change in each Zepbound (tirzepatide) trial as the FDA label reports it, every dose beside placebo, with trial size, length and side effects.

• Wegovy weight loss chart: STEP and OASIS trial results

  Body-weight change in each Wegovy (semaglutide) trial from the FDA label: 2.4 mg and 7.2 mg injections and the 25 mg tablet, each beside placebo.

• Ozempic vs Wegovy

  Ozempic and Wegovy both contain semaglutide but are separate FDA-approved products: indications, doses, forms and trials compared from the labels.

• Mounjaro vs Zepbound

  Mounjaro and Zepbound both contain tirzepatide but are separate FDA-approved products: indications, doses, forms and trials compared from the labels.

Investigational compounds are not approved medicines and are covered separately: see the retatrutide clinical trials.

Peptide Library is an independent educational resource. It is not affiliated with, sponsored or endorsed by Novo Nordisk or Eli Lilly; Ozempic, Wegovy, Mounjaro and Zepbound are trademarks of their owners and are named only to identify the products. This page summarizes FDA-approved prescribing information and published trials. It is not individual medical advice: dosing and any change to it are decided with a prescriber.